Fig. 1.

High Mobility Group Box 1 (HMGB1) concentrations were measured during radiochemotherapy (RT) as well as during follow-up (FU). While there were no consistent changes during treatment (a), HMGB1 levels decreased during follow-up in all patients (b). Comparing HMGB1 concentrations at baseline versus the last available samples during treatment, in eight patients concentrations increased, while three patients showed decreasing HMGB1 levels, indicated in gray (c). However, all HMGB1 concentrations at last follow-up were lower than initial levels (d). Cyan lines indicate means and standard errors for all patients